Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Navarra | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Obesity prevalence in elderly populations has increased in the last years, and the reduction of overweight and obesity is a priority target in populations of all age ranges worldwide. Obesity is a disease frequently accompanied by a pro-inflammatory state, in which metabolic functions may be compromised, and therefore there is a risk of developing comorbidities such as type-2 diabetes, hyperlipidemias, hypertension, atherosclerosis, etc. In this context, plant extracts are a good source of antioxidant compounds. Among these compounds, polyphenols have been shown to have an important antioxidant effect. Scientific evidence based on epidemiological studies suggest that flavonoids from the diet play an important role on the prevention of cardiovascular disease. Cocoa and related products are an important source of flavonoids, providing even more than tea or wine. Generally, benefits associated to cocoa consumption are related to the ability for improving lipid profile and insulin sensitivity, reducing blood pressure, platelet activity and improving endothelial dysfunction. Some studies have also shown an improvement of inflammatory conditions, mainly due to the capacity of the polyphenols contained to modify cellular transcription, and the secretion of proinflammatory cytokines in peripheral blood mononuclear cells, macrophages and lymphocytic strains. Therefore, the hypothesis of this study is that the consumption of cocoa extract-enriched prepared meals, within a hypocaloric diet, will help to reduce body weight and to improve cardiovascular risk factors compared to the same diet with standard prepared meals.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| control group, placebo | Placebo Comparator | This period will consist on a structured personalised hypocaloric diet containing ready prepared meals without extract added |
|
| Intervention group, cocoa extract | Experimental | This period will consist on a structured personalised hypocaloric diet containing ready prepared meals with cocoa extract added. Final cocoa extract daily intake will be of 1.4 g. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cocoa extract | Dietary Supplement | Participants will follow a hypocaloric diet during two periods of 4 weeks, each. Within these diets, participants will consume daily 2 ready prepared frozen meals containing cocoa extract (0.7 g per meal; 1.4g per day) or nothing (placebo). |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline of Plasma Oxidized LDL | Levels of LDL-ox in plasma will be analysed at the beginning and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline of fat mass content | Fat mass will be measured by bioelectric impedance and Dual X-ray absorptiometry at baseline and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Change from baseline of waist circumference |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| J. Alfredo Martinez, PhD, RN | University of Navarra, Pamplona, Spain | Principal Investigator |
| M. Angeles Zulet, PhD | University of Navarra, Pamplona, Spain | Study Chair |
| Santiago Navas-Carretero, PhD | University of Navarra, Pamplona, Spain | Study Chair |
| Idoia Ibero, M. Sc | University of Navarra, Pamplona, Spain | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Nutrition, Food Science, Physiology and Toxicology. University of Navarra | Pamplona | Navarre | 31008 | Spain |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26962189 | Derived | Ibero-Baraibar I, Perez-Cornago A, Ramirez MJ, Martinez JA, Zulet MA. An Increase in Plasma Homovanillic Acid with Cocoa Extract Consumption Is Associated with the Alleviation of Depressive Symptoms in Overweight or Obese Adults on an Energy Restricted Diet in a Randomized Controlled Trial. J Nutr. 2015 Apr 1;146(4):897S-904S. doi: 10.3945/jn.115.222828. | |
| 25527736 |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D050177 | Overweight |
| D009765 | Obesity |
| ID | Term |
|---|---|
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069956 | Chocolate |
| D057140 | Fast Foods |
| ID | Term |
|---|---|
| D005502 | Food |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |
| D019602 | Food and Beverages |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
Waist circumference will be measured with a measure tape at baseline and the end (4 weeks) of each intervention period |
| Baseline and 4 weeks |
| Change from baseline of hip circumference | Hip circumference will be measured with a measure tape at baseline and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Height | Baseline |
| Change from baseline of body weight | Baseline and 2 weeks |
| Change from baseline of body weight | Baseline and 4 weeks |
| Change from baseline of skinfolds | Tricipital, Bicipital, subscapular and suprailiac skinfolds will be measured at baseline and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Change from baseline of serum glucose levels | Serum glucose concentration will be measured in a fasting state at the beginning and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Change from baseline of serum insulin concentration | Serum insulin concentration will be measured in a fasting state at the beginning and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Change from baseline of serum free fatty acids concentration | Serum free fatty acids concentration will be measured in a fasting state at the beginning and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Change from baseline of serum total cholesterol concentration | Serum total cholesterol concentration will be measured in a fasting state at the beginning and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Change from baseline of serum HDL-cholesterol concentration | Serum HDL-cholesterol concentration will be measured in a fasting state at the beginning and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Change from baseline of serum LDL-cholesterol concentration | Serum LDL-cholesterol concentration will be measured in a fasting state at the beginning and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Change from baseline of serum triglycerides concentration | Serum triglycerides concentration will be measured in a fasting state at the beginning and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Change from baseline of serum total protein concentration | Serum total protein concentration will be measured in a fasting state at the beginning and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Change from baseline of serum transaminases concentration | Serum transaminases (AST & ALT) concentration will be measured in a fasting state at the beginning and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Change from baseline of serum homocystein concentration | Serum homocystein concentration will be measured in a fasting state at the beginning and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Change from baseline of Diastolic blood pressure | Diastolic blood pressure will be measured at baseline and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Change from baseline of Systolic blood pressure | Systolic blood pressure will be measured at baseline and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Change from baseline of Food intake | Food intake will be measured by a 72 h weighed food record at baseline and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Change from baseline of plasma PAI-1 concentration | Plasma PAI-1 concentration will be measured in a fasting state at the beginning and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Change from baseline of plasma malonyldialdehyde (MDA) concentration | Plasma MDA concentration will be measured in a fasting state at the beginning and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Change from baseline of plasma total antioxidant capacity (TAC) | Plasma TAC will be measured in a fasting state at the beginning and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Change from baseline of serum uric acid levels | Serum uric acid levels will be measured in a fasting state at the beginning and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Change from baseline of Glutathione peroxidase activity | Glutathione peroxidase activity will be measured in a fasting state at the beginning and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Change from baseline of plasma C-Reactive Protein levels | C-Reactive Protein levels will be measured in a fasting state at the beginning and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Change from baseline of plasma IL-6 levels | IL-6 levels will be measured in a fasting state at the beginning and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Change from baseline of plasma TNF-alpha levels | TNF-alpha levels will be measured in a fasting state at the beginning and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Personality Test | Personality will be evaluated through the NEO-PI-R test. | Baseline |
| Change from baseline of depression degree | Depression degree will be evaluated through the Beck depression inventory, the anxiety/STAI inventory and subjective anxiety and depression thermometer scale, at the beginning and the end of each intervention period | Baseline and 4 weeks |
| Change from baseline of health status | Health status will be evaluated through the SF-36v2 Health survey at the beginning and the end of each intervention period | Baseline and 4 weeks |
| Change from baseline of plasma VCAM-1 levels | VCAM-1 levels will be measured in a fasting state at the beginning and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Change from baseline of plasma ICAM-1 levels | ICAM-1 levels will be measured in a fasting state at the beginning and the end (4 weeks) of each intervention period | Baseline and 4 weeks |
| Cocoa Bioavailability | Metabolites from cocoa polyphenols will be analysed in plasma and urine at the beginning and the end of each intervention period in order to estimate the bioavailability of cocoa extract studied. | Baseline and 4 weeks |
| DNA damage | DNA ability to self-repair and DNA damage extent will be quantified through commet assay at the beginning and the end of each intervention period. | Baseline and 4 weeks |
| Ibero-Baraibar I, Azqueta A, Lopez de Cerain A, Martinez JA, Zulet MA. Assessment of DNA damage using comet assay in middle-aged overweight/obese subjects after following a hypocaloric diet supplemented with cocoa extract. Mutagenesis. 2015 Jan;30(1):139-46. doi: 10.1093/mutage/geu056. |
| 25434574 | Derived | Ibero-Baraibar I, Navas-Carretero S, Abete I, Martinez JA, Zulet MA. Increases in plasma 25(OH)D levels are related to improvements in body composition and blood pressure in middle-aged subjects after a weight loss intervention: Longitudinal study. Clin Nutr. 2015 Oct;34(5):1010-7. doi: 10.1016/j.clnu.2014.11.004. Epub 2014 Nov 11. |
| 24462367 | Derived | Ibero-Baraibar I, Abete I, Navas-Carretero S, Massis-Zaid A, Martinez JA, Zulet MA. Oxidised LDL levels decreases after the consumption of ready-to-eat meals supplemented with cocoa extract within a hypocaloric diet. Nutr Metab Cardiovasc Dis. 2014 Apr;24(4):416-22. doi: 10.1016/j.numecd.2013.09.017. Epub 2013 Nov 1. |
| D012816 |
| Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |